HIV and ID Observations Blog

Post-Exposure Prophylaxis for HCV Can’t Be Cost-Effective — But We Might End Up Recommending It Anyway Free

Is post-exposure prophylaxis for hepatitis C virus a no-brainer? Dr. Paul Sax asks this question in HIV and ID Observations.

Drug Watch


The FDA has approved the integrase inhibitor dolutegravir for treatment of HIV infection, in combination with other antiretrovirals.